These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

173 related items for PubMed ID: 7969908

  • 1. The dopamine D2 antagonist remoxipride acts in vivo on a subpopulation of dopamine D2 receptors.
    Ogren SO, Rosén L, Fuxe K.
    Neuroscience; 1994 Jul; 61(2):269-83. PubMed ID: 7969908
    [Abstract] [Full Text] [Related]

  • 2. Selective unilateral inactivation of striatal D1 and D2 dopamine receptor subtypes by EEDQ: turning behavior elicited by D2 dopamine receptor agonists.
    Giorgi O, Biggio G.
    Brain Res; 1990 Nov 12; 533(1):53-9. PubMed ID: 1982234
    [Abstract] [Full Text] [Related]

  • 3. Remoxipride shows low propensity to block functional striatal dopamine D2 receptors in vitro.
    Westlind-Danielsson A, Gustafsson K, Andersson I.
    Eur J Pharmacol; 1994 Dec 15; 288(1):89-95. PubMed ID: 7705472
    [Abstract] [Full Text] [Related]

  • 4. Pituitary and brain D2 receptor density measured in vitro and in vivo in EEDQ treated male rats.
    Ekman A, Eriksson E.
    Life Sci; 1991 Dec 15; 48(4):321-31. PubMed ID: 1824955
    [Abstract] [Full Text] [Related]

  • 5. Comparison of the effects of haloperidol, remoxipride and raclopride on "pre"- and postsynaptic dopamine receptors in the rat brain.
    Magnusson O, Fowler CJ, Mohringe B, Wijkström A, Ogren SO.
    Naunyn Schmiedebergs Arch Pharmacol; 1988 Apr 15; 337(4):379-84. PubMed ID: 2900472
    [Abstract] [Full Text] [Related]

  • 6. Comparison of the effects of remoxipride and raclopride on nigrostriatal and mesolimbic dopaminergic neuronal activity and on the secretion of prolactin and alpha-melanocyte-stimulating hormone.
    Eaton MJ, Tian Y, Lookingland KJ, Moore KE.
    Neuropsychopharmacology; 1992 Nov 15; 7(3):205-11. PubMed ID: 1326981
    [Abstract] [Full Text] [Related]

  • 7. EEDQ, a tool for ex vivo measurement of occupancy of D-1 and D-2 dopamine receptors.
    Nowak G, Arnt J, Hyttel J.
    Eur J Pharmacol; 1988 Aug 24; 153(2-3):309-11. PubMed ID: 3053212
    [Abstract] [Full Text] [Related]

  • 8. Binding characteristics of remoxipride and its metabolites to dopamine D2 and D3 receptors.
    Mohell N, Sällemark M, Rosqvist S, Malmberg A, Högberg T, Jackson DM.
    Eur J Pharmacol; 1993 Jul 06; 238(1):121-5. PubMed ID: 8405075
    [Abstract] [Full Text] [Related]

  • 9. Subchronic treatment of rats with remoxipride fails to modify sigma binding sites in the brain.
    Ericson H, Ross SB.
    Eur J Pharmacol; 1992 Jun 05; 226(2):157-61. PubMed ID: 1353452
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Comparison of the effects of dopamine D1 and D2 receptor antagonists on rat striatal, limbic and nigral dopamine synthesis and utilisation.
    Magnusson O, Mohringe B, Fowler CJ.
    J Neural Transm; 1987 Jun 05; 69(3-4):163-77. PubMed ID: 2957465
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Atropine acts in the ventral striatum to reduce raclopride-induced catalepsy.
    Alcock SJ, Hemsley KM, Crocker AD.
    Eur J Pharmacol; 2001 Jul 27; 424(3):179-87. PubMed ID: 11672560
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Specific involvement of striatal D1 and D2 dopamine receptors in the neuroleptic catalepsy in rats.
    Wardas J, Pietraszek M, Ossowska K, Wolfarth S.
    Pol J Pharmacol; 1995 Jul 27; 47(4):349-53. PubMed ID: 8616516
    [Abstract] [Full Text] [Related]

  • 20. Remoxipride, a new potential antipsychotic compound with selective antidopaminergic actions in the rat brain.
    Ogren SO, Hall H, Köhler C, Magnusson O, Lindbom LO, Angeby K, Florvall L.
    Eur J Pharmacol; 1984 Jul 20; 102(3-4):459-74. PubMed ID: 6149133
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.